Esperion Therapeutics (ESPR) Total Liabilities (2012 - 2026)

Esperion Therapeutics' Total Liabilities history runs 15 years deep, the most recent figure standing at $770.5 million for Q1 2026.

• Quarterly Total Liabilities rose 2.7% year-over-year to $770.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $770.5 million (up 2.7% YoY) and the FY2025 annual result came in at $767.9 million, up 4.82% from the prior year.
• Total Liabilities was $770.5 million for Q1 2026 at Esperion Therapeutics, roughly flat from $767.9 million in the prior quarter.
• Across five years, Total Liabilities topped out at $815.4 million in Q3 2025 and bottomed at $571.7 million in Q4 2022.
• A 5-year average of $677.2 million and a median of $667.4 million in 2024 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2023 — Total Liabilities retreated 1.76% — and 2025, when it increased 19.15%.
• Esperion Therapeutics' Total Liabilities stood at $571.7 million in 2022, then rose by 15.58% to $660.8 million in 2023, then rose by 10.86% to $732.5 million in 2024, then climbed by 4.82% to $767.9 million in 2025, then gained by 0.34% to $770.5 million in 2026.
• Business Quant data shows ESPR's Total Liabilities at $770.5 million in Q1 2026, $767.9 million in Q4 2025, and $815.4 million in Q3 2025.